



Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy

Paul Dowling, Dounia Bouragba, Elisa Negroni, Capucine Trollet, Margit Zweyer, Dieter Swandulla & Kay Ohlendieck

To cite this article: Paul Dowling, Dounia Bouragba, Elisa Negroni, Capucine Trollet, Margit Zweyer, Dieter Swandulla & Kay Ohlendieck (2026) Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy, Expert Review of Proteomics, 23:4-5, 109-120, DOI: [10.1080/14789450.2026.2669276](https://doi.org/10.1080/14789450.2026.2669276)

To link to this article: <https://doi.org/10.1080/14789450.2026.2669276>



© 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 06 May 2026.



[Submit your article to this journal](#)



Article views: 318










[View related articles](#)



[View Crossmark data](#)

Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy

Paul Dowling ^{a,b}, Dounia Bouragba ^c, Elisa Negroni ^c, Capucine Trollet ^c, Margit Zweyer ^d, Dieter Swandulla ^e and Kay Ohlendieck ^{a,b}

^aDepartment of Biology, Maynooth University, National University of Ireland, Maynooth, Ireland; ^bKathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland; ^cCenter for Research in Myology U974, Sorbonne Université, INSERM, Myology Institute, Paris, France; ^dGerman Centre for Neurodegenerative Diseases, Bonn, Germany; ^eInstitute of Physiology, Faculty of Medicine, University of Bonn, Bonn, Germany

ABSTRACT

Introduction: Clinical proteomics is an evolving discipline that aims to identify new biomarker candidates of human disease to improve diagnosis, prognosis, treatment monitoring and the discovery of novel therapeutic targets. This article outlines the pathoproteomic characterization of dystrophinopathies, which are classified as muscle wasting diseases due to mutations in the *DMD* gene.

Areas covered: The Special Report focuses on the proteomic profiling of progressive Duchenne muscular dystrophy of early childhood and more benign and later-onset Becker muscular dystrophy. The literature search on proteomics and biomarker discovery in dystrophinopathies was conducted with the standard scientific literature databases PubMed and Google Scholar for the preparation of the general text of this article.

Expert opinion: This report has outlined the biomedical value of the systematic proteomic characterization of tissue specimens and associated biofluids to establish novel biomarkers for monitoring clinical studies in muscular dystrophy. Both, mass spectrometry-based profiling approaches and high-plex/high-throughput proteomics platforms were shown to be suitable for the systematic study of complex changes versus adaptations in dystrophinopathy. The verification of promising disease indicators, especially minimally invasive biofluid markers of myonecrosis, chronic inflammation, disturbed energy metabolism and myofibrosis, using orthogonal methodology holds great potential for future clinical applications such as therapeutic monitoring.

ARTICLE HISTORY

Received 4 February 2026
Accepted 23 April 2026

KEYWORDS

Biomarker; Duchenne/Becker muscular dystrophy; dystrophinopathy; mass spectrometry; neuromuscular disease; proteomics

1. Introduction

A better understanding of the molecular pathogenesis of human disease and the systematic identification of robust protein biomarkers to establish reliable and cost-effective assay systems for the monitoring of therapeutic success are major aims of clinical proteomics [1–3]. Ideally, a combination of proteomic biomarkers is used to create a characteristic protein signature of a pathophysiological process for the optimization of differential diagnostics, prognostics and the determination of therapeutic threshold [4–6]. The pathoproteomic identification of novel therapeutic targets is another important application of mass spectrometry (MS) based biochemical profiling [7–9], in addition to the systematic usage of high-plex/high-throughput proteomics platforms [10–12]. This Special Report discusses the potential of proteomic analysis for detailed studies of patient specimens and to establish pathobiochemical tools to evaluate clinical applications to treat the group of neuromuscular disorders named dystrophinopathies [13–15], which include the main phenotypic diseases of Duchenne muscular dystrophy (DMD) [16] and Becker muscular dystrophy (BMD) [17].

The standard scientific literature databases Pubmed and Google Scholar were employed for the preparation of the general text of this article, using a combination of search terms including 'Duchenne muscular dystrophy,' 'Becker muscular dystrophy,' 'dystrophinopathy,' 'dystrophin,' 'mass spectrometry,' 'biomarker' and 'proteomics.' Identified publications on the proteomic identification and characterization of altered protein species in dystrophic skeletal muscles and associated biofluids were further screened for their relevance to the development of a biomarker signature of dystrophinopathy in order to comply with the reference limitations imposed for this type of article.

2. Dystrophinopathies

Dystrophinopathies are due to primary abnormalities in the *DMD* gene that cause an abnormal abundance and/or size of the dystrophin protein isoform Dp427-M [18]. **Figure 1** outlines the multi-promoter and 79-exon spanning *DMD* gene, which encodes eight dystrophin protein isoforms of varying molecular mass and tissue location, including Dp427-B (brain), Dp427-P (cerebellar Purkinje cells), Dp427-M (skeletal, cardiac and smooth muscle), Dp260-R (retina),

Article highlights

- Duchenne muscular dystrophy is a highly progressive muscle wasting disease of early childhood.
- Mass spectrometric screening and high-plex/high-throughput analysis platforms are ideal tools for the characterization of dystrophic muscle tissues and associated biofluids.
- Comparative tissue proteomics has revealed considerable changes in proteins involved in the excitation-contraction-relaxation cycle, signaling pathways, cellular stress response, the extracellular matrix and the cytoskeletal network.
- Biomarker discovery by biofluid proteomics has identified a variety of promising candidates for minimally invasive analysis.
- The future integration of multi-omics datasets and systems biological analyses will help to establish a comprehensive biomarker signature of X-linked muscular dystrophy.

Dp140-B/K (brain and kidney), Dp116-S (Schwann cells), Dp71-G (ubiquitous) and Dp40 (ubiquitous; enriched in the central nervous system) [19–21]. Notably, a variety of *DMD* gene mutation types lead to abnormalities in the full-length dystrophin isoform Dp427-M in muscle fibers and shorter dystrophin isoforms in other types of tissues [22]. As recently reviewed by Okubo [23], the broad genetic spectrum of dystrophinopathies is characterized by distinct *DMD* gene variants, such as small exonic deletions, large exonic deletions, exonic duplications, small exonic insertions or large exonic insertions, as well as small *DMD* gene variants,

including missense point mutations, splice site mutations, nonsense point mutations or mid-intronic mutations [24–26] (Figure 1). Thus, different mutations influence muscle dystrophin protein size and expression and can result in its absence, truncation or partial preservation [27–29]. Highly progressive DMD is characterized by out-of-frame mutations [16,18] and the almost complete loss of dystrophin [19,27–29], which is associated with extensive proteomic disturbances [30,31]. In contrast, in-frame deletions cause BMD [17,18] and are characterized by shortened but partially functional dystrophin molecules [19,27–29] and milder proteomic disturbances [32,33].

Severe forms of advanced dystroptology are characterized by chronic skeletal muscle wasting and impaired regenerative capacity [34–36], as well as multisystemic and body-wide abnormalities (Table 1), which are currently under investigation using proteomics [37]. These include late-onset cardiomyopathy, respiratory impairments, renal failure, fatty liver disease, bone fragility, scoliosis and gastrointestinal abnormalities, as well as neurological and behavioral deficiencies in a subset of DMD patients [22]. Non-skeletal muscle abnormalities might be associated with secondary body-wide disturbances, such as weakened cardiovascular function and the chronic shedding of muscle proteins into the circulatory system, or primary alterations in the expression of non-skeletal muscle dystrophins that directly trigger multisystem issues in a variety of tissues.





Figure 1. Overview of the *DMD* gene and dystrophin isoforms and their involvement in dystrophinopathy.

The diagram outlines the basic organization of the extremely large *DMD* gene and its promoter structure. Shown are the various tissue-specific dystrophin isoforms ranging in molecular mass from approximately 40 kDa to 427 kDa. The broad genetic spectrum of dystrophinopathies is presented, as well as the impact of *DMD* gene mutations on proteomic profiles.

Abbreviations used: BMD, Becker muscular dystrophy; CNS, central nervous system; DMD, Duchenne muscular dystrophy; Dp427-M, full-length muscle-specific dystrophin protein isoform of 427 kDa.

Table 1. Overview of primary skeletal muscle pathogenesis and multisystemic dysfunction in dystrophinopathy.

Organ system abnormalities	Pathobiochemical mechanisms	Cellular and physiological dysfunctions
Primary skeletal muscle degeneration	Primary deficiency in dystrophin isoform Dp427-M causes collapse of the dystrophin-associated glycoprotein complex	Disintegration of sarcolemmal integrity promoting contraction-induced membrane rupturing which renders contractile fibers more susceptible to necrosis
Skeletal muscle inflammation	Chronic myonecrosis evokes a sustained immune response involving the activation of macrophages and related immune cells	Skeletal muscle tissue damage linked to a chronic inflammatory response and the continuous release of inflammatory cytokines and signaling factors
Skeletal muscle fibrosis	Inflammation related triggering of reactive myofibrosis with increased collagen deposition	Skeletal muscle tissue scarring and matrisomal remodeling causing loss of muscle elasticity and cellular adaptability
Skeletal muscle adipogenesis	Chronic muscle wasting is associated with gradual fat substitution	Metabolic disturbances and unfavorable fat-to-muscle ratios in affected patients
Late-onset cardiomyopathy	Dystrophic phenotype is characterized by a disintegrating basement membrane and interstitial fibrosis	Cardiomyocyte dysfunction resulting in arrhythmias and heart failure
Cardio-respiratory syndrome	Cardiac and respiratory muscle weakness	Respiratory insufficiency and restrictive lung disease
Central nervous system abnormalities	Primary defects in brain dystrophins negatively affect neurons, synapses and glial cells	Cognitive deficiency influencing language, attention, emotions, social interactions and memory
Peripheral nervous system abnormalities	Defective neuromuscular connections	Impaired transmission at neuromuscular junctions
Liver disease	Fibrosis, atrophy and ectopic fat deposition	Metabolic dysfunction due to liver steatosis
Kidney failure	Impaired renal filtration and ectopic fat deposition	Dysfunction of the renal/urinary tract system
Endocrine disease	Hormonal disturbances and mild glucose intolerance	Endocrine imbalance negatively affects development and growth
Gastro-intestinal tract abnormalities	Gut motor dysfunction	Delayed gastric emptying, constipation
Skeletal disease	Abnormal bone-muscle crosstalk and decreased bone density	Fragile bones and spinal deformations

**Figure 2.** Overview of bioanalytical applications using clinical proteomics to investigate dystrophinopathies.

Listed is the starting material for proteomic investigations and a diagram outlining the basic domain structure of full-length muscle dystrophin and its binding sites, as well as a flowchart of proteomic analysis platforms to study dystrophinopathies.

Abbreviations used: BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; Dp427-M, full-length muscle-specific dystrophin protein isoform of 427 kDa; nNOS, neuronal nitric oxide synthase.

3. Clinical proteomics and biomarker discovery in DMD research

An important application of MS-based methodology in DMD/BMD research is the assessment of dystrophin levels in normal versus dystrophic muscle, as well as the monitoring of potential changes in dystrophin following therapeutic interventions. Notably, a variety of proteomic approaches have been optimized for the quantitation of dystrophin isoform Dp427-M in human skeletal muscle biopsy specimens [38–42] (Figure 2). Interestingly, the protein turnover of dystrophin and its associated dystroglycan complex following experimental exon skipping therapy was successfully determined by proteomics [43]. For a better understanding of the complex pathogenesis of DMD and BMD, systematic MS-based proteomic surveys of dystrophic skeletal muscle specimens [30–33], DMD myoblasts/myotubes [44], induced pluripotent stem cell (iPSC) derived DMD cell cultures [45], 3D-anchored DMD muscle cells [46] and biofluids (serum and urine) [47–59] have been carried out. Complementary results were achieved by the application of proteomic multi-plex/high-throughput analysis platforms, such as aptamer-based SOMAscan and ProteoMiner beads, for the screening of biofluids from corticosteroid-naïve [60–64] versus corticosteroid-treated DMD/BMD patients [65–67]. The serum biomarker signature of dystrophinopathy [59] was confirmed by biofluid proteomics using established animal models [68].

The comprehensive cataloging of proteome-wide alterations in dystrophin-deficient muscle cells and tissues is essential for improving our pathobiochemical understanding of the cellular mechanisms that underlie dystrophinopathy [30–33,44,45]. Discussions of key findings from proteomic studies that have focused on the characterization of DMD/BMD are available in reviews that give an overview of major achievements in dystrophinopathy research [5,37,59] including articles with a focus on individual biomarker candidates such as fatty acid binding protein FABP3 [69], carbonic anhydrase CA3 [70], and annexin isoform ANXA2 [71]. Importantly, for the establishment of a clinically useful biomarker signature of neuromuscular pathogenesis, especially protein changes in easily accessible biofluids, such as blood (serum/plasma), saliva or urine, are of considerable biomedical interest. It is encouraging that DMD biofluid analyses have established large cohorts of minimally invasive protein biomarkers that are suitable for repeated sampling and the monitoring of disease stage-specific alterations [59].

The main strength of biomedical proteomics is the user-friendly usage of MS techniques and/or protein arrays as convenient and robust high-throughput analysis platforms which have been optimized and streamlined over the last decade [3,72]. Widely employed bottom-up proteomics takes advantage of the biochemical properties of small peptides which can be easily separated by a variety of liquid chromatography methods, such as strong cation exchange and reversed-phase columns, used alone (1D-LC), in combination (2D-LC), as split-flow applications (SF-2D-LC) or in series (3D-LC). In MS-based analysis, small peptides ionize well and their fragmentation patterns are relatively predictable. This enables the routine analyses of complex protein mixtures from clinical specimens for the efficient

identification and quantification of distinct protein species and their potential role in pathophysiological processes. A cost-effective standard method of proteomics is presented by label-free quantification MS.

Disadvantages of proteomics are associated with both technical and biological limitations [72]. The initial purchase of state-of-the-art mass spectrometers and protein separation equipment is expensive, and considerable running costs are associated with proteomic analysis suites. The processing of samples involves a multi-step procedure that can be labor-intensive and be complicated if elaborate pre-fractionation processing is required or the removal of interfering chemicals, such as detergents. Poor protein identification can be due to unfavorable physicochemical properties of the analytes, incomplete proteolysis of the starting material and/or interfering contaminants. Routine bottom-up proteomics can result in only limited information on amino acid sequences which might not be comprehensive enough to properly identify a distinct proteoform, especially if sample size is restricted. Low-abundance proteins may be under-represented in bottom-up proteomics, and peptides derived from abundant proteins can weaken signals from low-copy number proteins. However, this issue can at least partially be addressed by immunoaffinity methods that deplete the most abundant proteins prior to proteomic analysis [72]. A difficult biological issue is the highly variable and complex proteome of any given biological system with a considerable dynamic range of protein concentrations and ongoing changes in post-translational modifications [7].

4. Muscle cell and tissue proteomics

As outlined in Figure 3, proteomics has been instrumental in the characterization of dystrophic muscle tissues and the concomitant identification of biofluid-associated disease indicators. The MS-based profiling of dystrophic skeletal muscle samples from DMD/BMD patients has great potential to reveal proteome-wide changes in myofibres and its tissue environment (Table 2). Studies by Capitanio et al. [30,32] using DMD and BMD skeletal muscle biopsies identified disturbances in the expression of proteoforms that are involved in the maintenance of the intracellular cytoskeleton and the extracellular matrix, the provision of contractile function, the regulation of Ca²⁺-homeostasis and protein metabolism, the cellular stress response, the inflammatory reaction to tissue damage and the regeneration of damaged contractile fibers. In addition, da Silva and coworkers [31] could show the concomitant decrease in sarcomeric protein species and a drastic increase in ubiquitination-related proteins, as well as alterations in proteoforms involved in key bioenergetic pathways in DMD. Of note, the imaging mass cytometric analysis of skeletal muscle specimens from BMD patients revealed different phases of muscle tissue degeneration with striking dissimilarities in the levels of specific collagen isoforms of the matrix in fibrotic versus non-fibrotic parts, in combination with alterations in markers of regenerative processes, inflammation and adipogenesis [33].

Proteomic investigations using DMD myoblasts and myotubes revealed changes in myogenic mechanisms, mRNA processing, cellular adhesion processes and organellar




Figure 3. Summary of select biomarker candidates to improve the therapeutic monitoring of dystrophinopathy.

The diagram outlines on the top left the main pathophysiological steps that lead to dystrophinopathy, and summarizes therapeutic approaches that aim at dystrophin restoration, muscle modification and muscle environment optimization at the top right of the figure. Select diagnostic, prognostic and pharmacodynamic biofluid marker candidates of dystrophinopathy are listed in the lower part of the figure.

Abbreviations used: A2M, alpha-2-macroglobulin; CA, carbonic anhydrase; CCL, C-C motif chemokine; CKM, creatine kinase M-type; COL, collagen; CST, cystatin; cTnC, cardiac troponin subunit C; cTnI, cardiac troponin subunit I; GLUD, glutamate dehydrogenase; FABP, fatty acid binding protein; FGG, fibrinogen gamma; FN, fibronectin; HP, haptoglobin; Hsp, heat shock protein; LDH, lactate dehydrogenase; MB, myoglobin; MDH, malate dehydrogenase; MLC, myosin light chain; MMP, matrix metalloproteinase; MYOM, myomesin; OPN, osteopontin; sTnC, skeletal muscle troponin subunit C; sTnI, skeletal muscle troponin subunit I; TTN, titin; UMOD, uromodulin.

Table 2. The potential of proteomics to improve differential diagnostics and the monitoring of clinical studies in Duchenne muscular dystrophy.

Clinically relevant analysis	Specimens	Methodology
Diagnostic quantification and mapping of dystrophin molecule	Skeletal muscle biopsy, cell lysates	Biochemical and mass spectrometry-based top-down analysis using immuno precipitation and/or gel electrophoretic separation
Characterization of the dystrophin-glycoprotein complex and its associated elements of the cytoskeleton and extracellular matrix	Skeletal muscle biopsy specimens	Mass spectrometry-based screening in combination with immuno precipitation, lectin agglutination, gel electrophoresis and/or density gradient ultracentrifugation
Comparative proteomic analysis of the dystrophic skeletal muscle phenotype following pharmacotherapy	Biofluids (serum, saliva, urine) and muscle biopsies	Biochemical and mass spectrometry-based bottom-up analysis of crude extracts, enriched preparations or subcellular fractions focusing on myonecrosis, myofibrosis and chronic inflammation
Comparative proteomic analysis of cardio-respiratory integrity following pharmacotherapy	Biofluids (serum, saliva, urine)	Mass spectrometry-based bottom-up analysis of total extracts or enriched preparations using cardiac-specific biomarkers
Comparative proteomic analysis of the dystrophic phenotype following gene therapy	Biofluids (serum, saliva, urine) and muscle biopsies	Mass spectrometry-based bottom-up analysis of crude extracts, enriched preparations or subcellular fractions following exon-skipping, viral transfer, genomic editing, stop codon read-through therapy or stem cell/myoblast transfer therapy
Comparative proteomic analysis of multisystemic and body-wide dysfunction in dystrophinopathy	Biofluids (serum, saliva, urine) and tissue biopsies	Mass spectrometry-based bottom-up analysis of crude extracts, enriched preparations or subcellular fractions using tissue-specific biomarkers

organization [44]. The analysis of DMD-derived iPSC preparations showed proteomic changes in the contractile apparatus, the matrisome, the cytoskeletal network and cell adhesion complexes [45]. The findings from this still limited number of comprehensive proteomic profiling studies of human dystrophic muscle cells agree with the vast knowledge that was

gained from investigating many different subtypes of skeletal muscle preparations derived from dystrophic animal models of DMD [73–76]. Overall, proteomics could show that the deficiency in dystrophin and associated reduction in its sarcolemmal glycoprotein complex triggers massive alterations in the skeletal muscle proteome, which in turn reflects the

pathophysiological severity of DMD/BMD pathology. A large number of novel tissue-associated biomarker candidates of myonecrosis, inflammation and reactive myofibrosis could be identified [30–33]. Studies on the cardiac proteome and dystrophinopathy-associated cardiomyopathy have mostly focused on animal models of DMD, such as the DMD pig and *mdx*-type mice. Of note, these investigations have established marked differences between skeletal and cardiac muscle proteomic signatures [77–79].

5. Biofluid proteomics

Biofluid proteomics of DMD [59] revealed altered levels of both previously established general marker proteins of skeletal muscle damage and novel indicators of dystrophinopathy-related myofiber degeneration and myofibrosis. Proteomic screening studies of DMD serum samples by Spitali et al. [61] who used aptamer-based SOMAscan screening and Johanssen et al. [58] who employed immuno assays combined with peptide quantification by parallel reaction monitoring MS analysis identified a considerable number of biomarker candidates. These investigations and a large number of other proteomic studies of biological fluids from patients and animal models [47–56,58–68] identified an impressive array of promising biomarker candidates.

Identified marker proteins derived from (i) the sarcomere (troponin subunit TnI of the regulatory complex of the actin-containing thin filament; myosin light chain MLC3 of the myosin-containing thick filament; titin TTN fragments of the gigantic half-sarcomere spanning titin filament; myomesin isoform MYOM3 of the M-line structure), (ii) the cytosol (a variety of glycolytic enzymes including phosphoglycerate mutase, lactate dehydrogenase and pyruvate kinase; CO₂-converting enzymes carbonic anhydrase isoforms CA1 and CA3; muscle-specific oxygen-binding protein myoglobin MB; muscle-associated fatty acid binding protein FABP3; M-type creatine kinase CKM), and (iii) mitochondria (mitochondrial malate dehydrogenase MDH2 of the citric acid cycle). Additional biomarker candidates are represented by alpha-2-macroglobulin (A2M), the muscle growth inhibiting myokine myostatin and tumor necrosis factor receptor. These proteins can be classified according to biological function and/or subcellular localization into contractile apparatus proteins (TTN, TnI, MLC3, MYOM3), cytosolic enzymes (CA1, CA3, CKM, glycolytic enzymes), mitochondrial proteins (MDH2) and metabolite transporters (FABP3, MB), plus various cellular stress proteins and signaling elements [49–68]. Biofluid proteomics also identified serum-associated markers of reactive myofibrosis, including collagens, fibronectin and osteopontin, as well as matrix metalloproteinases (MMP9) and their tissue inhibitors [47,48,59].

Based on the identification in numerous proteomic studies that have evaluated changes in DMD/BMD biofluids and being confirmed by verification analyses [80], especially promising markers (in conjunction with the already frequently used M-type creatine kinase) [81–83] are N- and C-terminal fragments of titin [49,84], the muscle-specific carbonic anhydrase isoform CA3 that is enriched in slow myofibers [70], the M-line protein myomesin MYOM3 [51], fatty acid binding protein 3

(FABP3) [69], mitochondrial malate dehydrogenase MDH2 [85], myosin light chain MYL3 and skeletal muscle troponin I (sTnI) [49–68]. Table 3 lists minimally invasive biofluid marker candidates and gives information on their protein name, their subcellular origin, monitoring potential and representative references. Most of these identified biomarkers are highly elevated in DMD, moderately increased in BMD and show relatively small fluctuations in normal individuals. A significantly increased concentration of A2M [58] and MYOM3 [51] is clearly associated with DMD progression. Both proteins can potentially be utilized as therapy-responsive markers that are sensitive to the restoration of dystrophin. Pharmacotherapeutic-responsive markers to corticosteroid treatment were identified as CKM, TnI, TnC, MLC3, MYOM3 and pro-inflammatory proteins [64–66]. Increased levels of serum CA3 and FABP3 correlate well with clinical milestones [69,70]. The characterization of respiratory performance has revealed cellular alterations in the dystrophic and highly fibrotic diaphragm, triggering weakness in this major muscle of inspiration. Severe diaphragm fibrosis was shown to be associated with elevated levels of fibronectin, osteopontin and collagens in muscle tissues [75,76] and is reflected by increased levels of ECM proteins in serum [47,48]. Cardiac cTnI and cTnI, listed in Table 3, are potential markers of dystrophinopathy-associated cardiomyopathy, and the CA3/MB ratio might be suitable to differentiate between the degree of cardiac versus skeletal muscle wasting [70].

In both, the analysis of patient specimens and animal models, cytokines, chemokines and myokines have been identified as potential markers of the immune response, degeneration-regeneration cycles and cellular disturbances in dystrophinopathy. The recruitment of macrophages, neutrophils, eosinophils and a variety of T-cells was shown to be associated with elevated levels of cytokines, including tumor necrosis factor TNF α and a large variety of interleukins [65,86–88].

6. Proteomic monitoring of future clinical DMD studies

As illustrated in Figure 3, a variety of novel therapeutic approaches have been evaluated in preclinical and clinical settings to counteract the main symptoms of dystrophinopathy, including advanced pharmacotherapy, cell-based therapy and gene therapeutic approaches at the level of both mRNA and DNA [16,21,89]. Standard care of DMD patients [90] includes cardiovascular management using treatment regimens with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-adrenergic receptor blockers and diuretics for cardioprotection [91]. This is accompanied by respiratory management, orthopedic interventions, physical therapy and optimized nutrition [92–94]. At later stages of DMD, ventilatory support has to be applied to address the cardiorespiratory syndrome and often life-threatening cardiomyopathic complications [95]. To address the primary skeletal muscle disease and preserve motor function, potent anti-inflammatory glucocorticosteroids, such as prednisolone, deflazacort and the more recently introduced agent vamorolone, form an integral part of supportive therapy in DMD [96–

Table 3. Promising and minimally invasive proteomic biomarker candidates for the improved differential diagnosis, prognosis and therapeutic monitoring of dystrophinopathies. Most listed studies have been carried out with serum specimens. An elevated concentration of fragments of the giant titin protein was also established in urine samples. Most identified biomarkers are highly elevated in DMD, moderately increased in BMD and show relatively small fluctuations in normal individuals. However, a variety of factors such as age, general disease status, side effects from pharmacotherapy, surgical procedures and the circadian rhythm can influence the concentration of certain muscle damage markers.

Biomarker candidate	Subcellular origin	Monitoring potential	References
Titin; amino- and carboxy-terminal TTN fragments	Half-sarcomere spanning giant TTN-filament in myofibers	Disintegration of auxiliary sarcomeric TTN-filament	[49,54,61,84]
Carbonic anhydrase isoform CA3, enriched in slow type I skeletal muscles	Sarcosol	Disintegration of sarcolemmal barrier function and abnormal CO ₂ -removal	[50,54,57,61–63,70]
Fatty acid binding protein isoform FABP3 (heart-type hFABP), present in heart and skeletal muscle	Sarcosol	Disintegration of sarcolemmal barrier function and abnormal fatty acid transportation in muscles	[50,61–63,69]
Myomesin MYOM3	Sarcomeric M-line structure	Disintegration of the sarcomere	[51,54,58,61]
Myoglobin MB	Sarcosol	Disintegration of sarcolemmal barrier function and abnormal O ₂ -transport	[50,54,61]
Creatine kinase CKM (muscle type)	Sarcosol	General muscle damage	[50,54,58,61,63]
Malate dehydrogenase MDH2, mitochondrial	Mitochondrial matrix	Mitochondrial dysfunction; impaired citric acid cycle	[60,61,85]
Troponin sTnC and sTnI (slow and fast isoforms)	Skeletal muscle sarcomeric thin actin-containing filament	Disintegration of contractile actomyosin apparatus	[50,61–63]
Myosin light chain MLC3, slow skeletal muscle	Skeletal muscle sarcomeric thick myosin-containing filament	Disintegration of contractile actomyosin apparatus	[54,61]
Alpha-2-macroglobulin A2M	Plasma protein	Pharmacodynamic marker of dystrophin restoration	[58]
Muscle carbonic anhydrase CA3 / muscle and heart myoglobin ratio	Sarcosol; muscle-specific CA3 versus cardiac/muscle MB	Evaluation of cardiomyopathy versus skeletal muscle degeneration	[70]
Matrisomal markers (FN, COL-VI, MMP9, OPN)	Extracellular matrix (basal lamina, endomysium, perimysium)	Reactive myofibrosis characterized by structural remodeling and excessive collagen deposition	[47,48,59,61]
Fibrinogen FGG gamma chain	Extracellular matrix niche and perivascular areas of dystrophic muscles	Muscle tissue injury, myofibrosis and inflammation	[58,61–63]
Glycolysis-associated enzymes (GPI, PFK, ALDO, TPI, PGAM, ENO, PKM, LDH, PYGM)	Sarcosol	Bioenergetic disturbances of carbohydrate metabolism,	[54,57,58,61–63]
CKM, TnI, TnC, MYL3, MYOM3 and pro-inflammatory proteins	Sarcosol, contractile apparatus and inflammation-associated proteins	Evaluation of effect of corticosteroid treatment	[64–66]
Troponin cTnC, cTnI, cardiac muscle	Cardiac sarcomeric thin actin-containing filament	Cardiomyopathy	[50,61]

Abbreviations used: A2M, alpha-2-macroglobulin; ALDO, aldolase; CA, carbonic anhydrase; CKM, muscle-type creatine kinase; COL, collagen; cTnC, cardiac troponin subunit C; cTnI, cardiac troponin subunit I; ENO, enolase; FABP, fatty acid binding protein; FGG, fibrinogen gamma chain; FN, fibronectin; GPI, phosphoglucose isomerase; LDH, lactate dehydrogenase; MDH, malate dehydrogenase; MMP, matrix metalloproteinase; MYOM, myomesin; OPN, osteopontin; PFK, phosphofructokinase; PGAM, phosphoglycerate mutase; PKM, pyruvate kinase; PYGM, glycogen phosphorylase; sTnC, skeletal muscle troponin subunit C; sTnI, skeletal muscle troponin subunit I; TPI, triosephosphate isomerase (TPI); TTN, titin.

98]. For DMD boys aged 6 and older, treatment with Givinostat (Duvyzat), a histone deacetylase inhibitor drug [99], was shown to have great potential to counteract inflammation and reactive myofibrosis, and exhibiting a positive effect on skeletal muscle regeneration [100]. Of note, the recent integration of open-access proteomic and transcriptomic datasets with *in silico* analyses has identify dysregulated pathways that might be reversed by existing drugs, such as inhibition of the sodium-glucose cotransporter-2 by the agent SGLT2i that could trigger anti-inflammatory and anti-fibrotic effects in dystrophic muscles [101].

The development of dystrophin restoration therapy for advanced DMD treatment includes adeno-associated virus (AAV) mediated gene transfer, stop codon read-through, genome editing, exon skipping, stem cell transfer and myoblast transfer [16,21,89]. Dystrophin quantification was successfully carried out by parallel reaction monitoring of human muscle biopsies [39]. Walsh and coworkers [42] have evaluated a potential DMD gene therapy drug during the early phase of a clinical study using MS-based methodology. The investigation aimed at assessing the usefulness of AAV-based gene replacement therapy using mini-dystrophin constructs. Immunoaffinity liquid

chromatography-tandem MS analysis was employed for protein identification emphasizing the usefulness of clinical proteomics. Thus, surrogate biomarkers are suitable for testing the efficacy and safety of gene therapy. Similar studies are under way to determine the proteomic profile of dystrophic skeletal muscles following exposure to new agents used in gene therapy.

Muscle modifier therapies aim at utrophin upregulation to substitute for dystrophin deficiency, myostatin inhibition, modulation of muscle contraction, modification of excitation-contraction coupling and satellite cell enhancement [16,21,102]. Muscle environment optimization therapy involves histone deacetylase inhibition, anti-inflammatory therapy, blood flow enhancement, anti-oxidants therapy, enhanced growth hormone secretion, modulation of the cellular stress response and anti-fibrotic treatment [16]. The above described novel proteomic markers of DMD pathogenesis [4,5,30–33,44–75], in addition to indicators of abnormal whole-body multisystemic changes including indicators of chronic inflammation, liver disease, kidney failure and cardiomyopathy [22,37,77–79], should be ideal candidates for developing a robust biomarker signature for evaluating new DMD treatment protocols (Figure 3).

7. Conclusion

As outlined in this Special Report, proteomics is a suitable bioanalytical platform to study the underlying mechanisms of the molecular and cellular pathogenesis of neuromuscular disease, and identify and characterize novel biomarker candidates of myofiber degeneration versus adaptive responses. In the field of dystrophinopathy research, proteomics has been instrumental for the quantitation of dystrophin and its associated sarcolemmal glycoprotein complex, as well as the detailed analysis of the wider dystrophin complexome consisting of elements of the extracellular matrix and the intracellular cytoskeletal network. Comparative proteomic studies have elucidated in detail a variety of alterations in the heterogeneous cellular and acellular skeletal muscle niche due to different types of *DMD* gene mutations. Primary genetic abnormalities lead to alterations in the abundance and/or size of the membrane cytoskeletal protein dystrophin which is intrinsically associated with various forms of dystrophinopathy, i.e. severe DMD or more benign BMD. Extensive MS-based screening and multiplex/high-throughput analyses have demonstrated that the class of mutation in the extremely large *DMD* gene has differential effects on the extent of proteomic changes in dystrophic muscle tissues. Besides considerable disturbances of the protein constituents of voluntary myofibers and their cellular environment due to myonecrosis, chronic inflammation, fat substitution and reactive myofibrosis, deficiency in Dp427-M also affects cardiac and smooth muscles in dystrophinopathy.

Future developments in the field of clinical proteomics will hopefully (i) upgrade the overall bioanalytical workflow, (ii) involve more streamlined sample handling, (iii) improve protein and peptide separation, (iv) use more sensitive protein identification by peptide MS analysis, (v) enhance the applications of systems bioinformatics leading to superior coverage of protein identification in small samples, such as single cell or subcellular preparations, and (vi) utilize artificial intelligence (AI) and Machine Learning (ML) algorithms for the improved interpretation of complex and high-throughput data, and thereby decisively accelerate the discovery rate of novel biomarkers and predicting clinical outcomes.

8. Expert opinion

The main analytical approaches of modern MS-based proteomics can be divided into top-down analyses, which focus on the detailed characterization of isolated proteoforms and their dynamic post-translational modifications, and bottom-up proteomics, which examines complex protein mixtures in a peptide-centric way for the identification of distinct protein species [72]. While top-down proteomics requires the purification of proteins of interest, the comparative screening by bottom-up proteomics can be carried out with crude tissue samples, isolated cells, subcellular fractions or complex biofluids following proteolytic digestion of the protein constituents. Both biochemical approaches can be employed in basic biomedical research, applied clinical chemistry and biomarker characterization. The biochemical knowledge from proteomics can now be used to widen the comprehensiveness of the biomarker signature of DMD/BMD pathogenesis, especially for the evaluation of future clinical studies and pharmacological trials. Since different *DMD*

gene mutations have been shown to exhibit a considerable impact on proteomic profiles in skeletal muscles and other tissue types, the application of integrative research strategies would be helpful for a systems biological understanding of dystrophinopathy [37].

Proteomics-based biomarker discovery, as outlined in this article, holds promise to improve various clinically relevant aspects in the field of dystrophinopathy. However, proteomic screening for the routine analysis of patient specimens would not be a realistic undertaking due to its enormous costs and limited access to specialized equipment in the clinical setting, but novel biomarkers that have been identified by proteomics and then been verified by orthogonal techniques should be useful to improve many clinically relevant aspects. This could include sample screening, differential diagnosis, prognosis and therapeutic monitoring. High-plex/high-throughput proteomics or MS-based analyses are not suitable to be directly used as routine analysis tools, but the field of clinical chemistry can build on proteomic findings and use newly established markers as potential parameters that would improve clinical measurements. Proteomics can certainly be useful for studying variations in natural history clinical studies that investigate the progression of a pathophysiological process and its main symptoms. The medical impact and response to therapeutic interventions, including potential differences in phenotype/genotype correlations, would be another aspect that could be studied by proteomic surveys. That could include the determination of disease severity before full manifestation of skeletal muscle wasting in BMD versus DMD.

The successful application and long-term treatment viability of combination therapy to halt or even reverse skeletal muscle wasting and associated multisystemic complications, such as cardiomyopathy, respiratory weakness, renal failure, liver atrophy and scoliosis in DMD/BMD, will heavily depend on the robust monitoring with proper biomarker assay systems. Optimized protein markers should be highly useful to determine the biomedical strength versus potential weaknesses of innovative pharmacotherapy or advanced gene/cell therapy approaches. In this regard, proteomic markers are ideal biomolecules to improve newborn screening, differential diagnosis, clinical predictions and continuous therapeutic monitoring of dystrophinopathy. Following the proper validation of proteomic findings using orthogonal verification methodology, such as immunoblotting, confocal microscopy, enzyme assays, protein binding studies and physiological experiments, the best protein markers should be chosen to develop a comprehensive set of surrogate biomarkers [103]. These indicators of muscle disease progression and clinical endpoints of DMD pathogenesis should then be able to differentiate between the detrimental effects that are generated by myofiber degeneration, chronic inflammation, adipogenesis and reactive myofibrosis, and how these pathological mechanisms can be reversed by novel therapeutics.

In relation to drug utilization, protein biomarkers can be used to predict and scrutinize a drug's safety by quantifying biological responses and identifying inflammation, stress or

organ damage caused by therapeutic interventions. This is especially relevant for virus-associated gene therapy and potential body-wide complications [104]. An interesting cost-effective and translational approach for future therapeutic discovery to counteract dystrophin deficiency is a drug repurposing strategy that combines information from open-access proteomic data and transcriptomic results with *in silico* analyses [101]. The systematic application of integromics by combining multi-omics datasets with systems biological analysis should be able to identify dysregulated pathways and aberrant signaling mechanisms in DMD/BMD that can potentially be reversed by existing pharmacological agents and thereby mitigate disease progression in dystrophinopathies.

Alternative biomarker discovery methods to MS-based bottom-up proteomics would be the systematic screening of proteins of interest with (i) standardized biochemical techniques such as enzyme-linked immunosorbent assay systems, and immunochemical approaches using dot blots, immunoblots and/or immunoprecipitation, (ii) cell biological methodology, including immunofluorescence microscopy and flow cytometry, (iii) the utilization of computational biological tools for the bioinformatic assessment of multi-omics findings integrating results from genomics, transcriptomics, proteomics, metabolomics and cytomics, and (iv) commercial affinity-based proteomics platforms (e.g. Olink, SomaScan) with improved sensitivity and throughput of biofluid proteome analysis, allowing for the rapid and parallel measurement of thousands of proteins.

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Funding

This manuscript was supported by the Kathleen Lonsdale Institute for Human Health Research at Maynooth University, Research Ireland and Campus France [Ulysses/2024/5], Infrastructure Awards by Science Foundation Ireland [SFI-12/RI/2346/3] and Research Ireland [23/RI/1203], the Agence Nationale de la Recherche [ANR, «EpiMUSE» grant # ANR-22-CE14-0068; “FibroDys” grant #ANR-24-CE14-5209; “CPJ” grant #ANR-24-CPJ1-0122-01], INSERM, Sorbonne University, and Association Institut de Myologie.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships.

Acknowledgments

The authors wish to thank our many national and international colleagues for their continued support of our skeletal muscle proteomics project.

All listed authors fully adhere to the authorship criteria established by the International Committee of Medical Journal Editors (ICMJE). Each author has made substantial contributions to the conception or design

of the work, or the acquisition, analysis, or interpretation of data; has participated in drafting or critically revising the manuscript for important intellectual content; has given final approval of the version to be published; and agrees to be accountable for all aspects of the work in ensuring its accuracy and integrity.

Author contributions

CRediT: **Paul Dowling**: Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing; **Dounia Bouragba**: Writing – review & editing; **Elisa Negroni**: Writing – review & editing; **Capucine Trollet**: Funding acquisition, Writing – review & editing; **Margit Zweyer**: Writing – review & editing; **Dieter Swandulla**: Writing – review & editing; **Kay Ohlendieck**: Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing.

ORCID

Paul Dowling  <http://orcid.org/0000-0002-9290-9267>
 Dounia Bouragba  <http://orcid.org/0009-0000-0352-0843>
 Elisa Negroni  <http://orcid.org/0000-0001-8302-2544>
 Capucine Trollet  <http://orcid.org/0000-0002-4838-3712>
 Margit Zweyer  <http://orcid.org/0000-0001-5615-1869>
 Dieter Swandulla  <http://orcid.org/0000-0003-0923-7090>
 Kay Ohlendieck  <http://orcid.org/0000-0002-6266-4510>

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest () to readers.**

- Rodland KD, Zhang B. Toward real clinical utility: leveraging comprehensive cancer proteomic datasets for clinical insight. *Expert Rev Proteomics*. 2025;22(10):375–387. doi: [10.1080/14789450.2025.2580647](https://doi.org/10.1080/14789450.2025.2580647)
- Guo T, Steen JA, Mann M. Mass-spectrometry-based proteomics: from single cells to clinical applications. *Nature*. 2025;638(8052):901–911. doi: [10.1038/s41586-025-08584-0](https://doi.org/10.1038/s41586-025-08584-0)
- Werner T, Fahrner M, Schilling O. Advancements in mass spectrometry-based proteomics: a new era in pathology research and diagnostics. *Pathologie (Heidelb)*. 2024;45(Suppl 1):56–62.
- Dowling P, Murphy S, Zweyer M, et al. Emerging proteomic biomarkers of X-linked muscular dystrophy. *Expert Rev Mol Diagn*. 2019;19(8):739–755. doi: [10.1080/14737159.2019.1648214](https://doi.org/10.1080/14737159.2019.1648214)
- Al-Khalili Szigyarto C. Duchenne muscular dystrophy: recent advances in protein biomarkers and the clinical application. *Expert Rev Proteomics*. 2020;17(5):365–375. doi: [10.1080/14789450.2020.1773806](https://doi.org/10.1080/14789450.2020.1773806)
- Birhanu AG. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. *Clin Proteomics*. 2023;20(1):32. doi: [10.1186/s12014-023-09424-x](https://doi.org/10.1186/s12014-023-09424-x)
- Mann SP, Treit PV, Geyer PE, et al. Ethical principles, constraints and opportunities in clinical proteomics. *Mol Cell Proteomics*. 2021;20:100046. doi: [10.1016/j.mcpro.2021.100046](https://doi.org/10.1016/j.mcpro.2021.100046)
- Korchak JA, Stephen Yi S, Kelleher NL, et al. Proteoform medicine: characterizing and targeting protein forms in human disease. *Nat Rev Genet*. 2026;27(4):271–291. doi: [10.1038/s41576-025-00915-1](https://doi.org/10.1038/s41576-025-00915-1)
- Bernardini C, Däther M, Traube FR. Advances and applications of spatial proteomics: from organellar maps to clinical translation. *Chembiochem*. 2026;27(1):e202500616. doi: [10.1002/cbic.202500616](https://doi.org/10.1002/cbic.202500616)
- Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. *Nature*. 2023;622(7982):348–358. doi: [10.1038/s41586-023-06563-x](https://doi.org/10.1038/s41586-023-06563-x)
- Li Y, Tam WW, Yu Y, et al. The application of aptamer in biomarker discovery. *Biomark Res*. 2023;11(1):70. doi: [10.1186/s40364-023-00510-8](https://doi.org/10.1186/s40364-023-00510-8)

12. Huang J, Chen X, Fu X, et al. Advances in aptamer-based biomarker discovery. *Front Cell Dev Biol.* 2021;9:659760. doi: 10.3389/fcell.2021.659760
13. Andrews JG, Galindo MK, Thomas S, et al. DMD gene and dystrophinopathy phenotypes associated with mutations: a systematic review for clinicians. *J Clin Neuromuscul Dis.* 2023;24(4):171–187. doi: 10.1097/CND.0000000000000436
14. Saad FA, Siciliano G, Angelini C. Advances in dystrophinopathy diagnosis and therapy. *Biomolecules.* 2023;13(9):1319. doi: 10.3390/biom13091319
15. Jayaraman D, Ghosh PS. Dystrophinopathies. *Continuum (Minneapolis, Minn).* 2025;31(5):1462–1485. doi: 10.1212/cont.0000000000001618
16. Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. *Nat Rev Dis Primers.* 2021;7(1):13. doi: 10.1038/s41572-021-00248-3
- **Excellent review outlining the pathogenesis of dystrophinopathy.**
17. Straub V, Guglieri M. An update on Becker muscular dystrophy. *Curr Opin Neurol.* 2023;36(5):450–454. doi: 10.1097/WCO.0000000000001191
18. Guiraud S, Aartsma-Rus A, Vieira NM, et al. The pathogenesis and therapy of muscular dystrophies. *Annu Rev Genomics Hum Genet.* 2015;16(1):281–308. doi: 10.1146/annurev-genom-090314-025003
19. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. *Lancet Neurol.* 2003;2(12):731–740. doi: 10.1016/s1474-4422(03)00585-4
20. Culligan KG, Mackey AJ, Finn DM, et al. Role of dystrophin isoforms and associated proteins in muscular dystrophy (Review). *Int J Mol Med.* 1998;2(6):639–648. doi: 10.3892/ijmm.2.6.639
21. Łoboda A, Chamberlain JS, Dulak J. Genetic strategies for therapy of Duchenne muscular dystrophy. *Mol Ther Nucleic Acids.* 2025;36(4):102759. doi: 10.1016/j.omtn.2025.102759
22. Ohlendieck K, Swandulla D. Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy. *Pflugers Arch.* 2021;473(12):1813–1839. doi: 10.1007/s00424-021-02623-1
23. Okubo M. Molecular genetics of dystrophinopathy. *J Hum Genet.* 2025. doi: 10.1038/s10038-025-01357-7
24. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. *Hum Mutat.* 2015;36(4):395–402. doi: 10.1002/humu.22758
25. Gambetta KE, McCulloch MA, Lal AK, et al. Diversity of dystrophin gene mutations and disease progression in a contemporary cohort of Duchenne muscular dystrophy. *Pediatr Cardiol.* 2022;43(4):855–867. doi: 10.1007/s00246-021-02797-6
26. Amr K, Fahmy N, El-Kamah G. Genomic insights into Duchenne muscular dystrophy: analysis of 1250 patients reveals 30% novel genetic patterns and 6 novel variants. *J Genet Eng Biotechnol.* 2024;22(4):100436. doi: 10.1016/j.jgeb.2024.100436
27. Hoffman EP, Kunkel LM. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. *Neuron.* 1989;2(1):1019–1029. doi: 10.1016/0896-6273(89)90226-2
28. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. *Am J Hum Genet.* 1989;45(4):498–506.
29. de Feraudy Y, Ben Yaou R, Wahbi K, et al. Very low residual dystrophin quantity is associated with milder dystrophinopathy. *Ann Neurol.* 2021;89(2):280–292. doi: 10.1002/ana.25951
30. Capitanio D, Moriggi M, Torretta E, et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. *J Cachexia Sarcopenia Muscle.* 2020;11(2):547–563. doi: 10.1002/jcsm.12527
- **Study outlines the detailed proteomic profiling of DMD pathogenesis.**
31. da Silva JCT, Nogueira MRA, da Silva YM, et al. Label-free proteomic analysis of Duchenne and Becker muscular dystrophy showed decreased sarcomere proteins and increased ubiquitination-related proteins. *Sci Rep.* 2025;15(1):3293. doi: 10.1038/s41598-025-87995-5
- **Detailed proteomic analysis of DMD-related changes.**
32. Capitanio D, Moriggi M, Barbacini P, et al. Molecular fingerprint of BMD patients lacking a portion in the rod domain of dystrophin. *Int J Mol Sci.* 2022;23(5):2624. doi: 10.3390/ijms23052624
33. Piñol-Jurado P, Verdú-Díaz J, Fernández-Simón E, et al. Imaging mass cytometry analysis of Becker muscular dystrophy muscle samples reveals different stages of muscle degeneration. *Sci Rep.* 2024;14(1):3365. doi: 10.1038/s41598-024-51906-x
34. Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. *Cell Mol Life Sci.* 2021;78(11):4867–4891. doi: 10.1007/s00018-021-03821-x
35. Kodippili K, Rudnicki MA. Satellite cell contribution to disease pathology in Duchenne muscular dystrophy. *Front Physiol.* 2023;14:1180980. doi: 10.3389/fphys.2023.1180980
36. Dowling P, Swandulla D, Ohlendieck K. Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction. *Eur J Transl Myol.* 2023;33(4):11856. doi: 10.4081/ejtm.2023.11856
37. Dowling P, Trollet C, Negroni E, et al. How can proteomics help to elucidate the pathophysiological crosstalk in muscular dystrophy and associated multi-system dysfunction? *Proteomes.* 2024;12(1):4. doi: 10.3390/proteomes12010004
38. Brown KJ, Marathi R, Fiorillo AA, et al. Accurate quantitation of dystrophin protein in human skeletal muscle using mass spectrometry. *J Bioanal Biomed.* 2012;4(Suppl 7):001. doi: 10.4172/1948-593X.S7-001
39. Canessa EH, Goswami MV, Alayi TD, et al. Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM). *J Mass Spectrom.* 2020;55(2):e4437. doi: 10.1002/jms.4437
40. Farrokhi V, Walsh J, Palandra J, et al. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. *Gene Ther.* 2022;29(10–11):608–615. doi: 10.1038/s41434-021-00300-7
41. Tominari T, Takatoya M, Matsubara T, et al. Establishment of a triple quadrupole HPLC-MS quantitation method for dystrophin protein in mouse and human skeletal muscle. *Int J Mol Sci.* 2023;25(1):303. doi: 10.3390/ijms25010303
42. Walsh J, Palandra J, Duriga N, et al. Dystrophin/mini-dystrophin expression analysis by immunoaffinity liquid chromatography-tandem mass spectrometry after gene therapy for DMD. *Gene Ther.* 2025;32(6):573–580. doi: 10.1038/s41434-025-00554-5
43. Novak JS, Spathis R, Dang UJ, et al. Interrogation of dystrophin and dystroglycan complex protein turnover after exon skipping therapy. *J Neuromuscul Dis.* 2021;8(s2):S383–S402. doi: 10.3233/JND-210696
44. Goswami MV, Tawalbeh SM, Canessa EH, et al. Temporal proteomic profiling during differentiation of normal and dystrophin-deficient human muscle cells. *J Neuromuscul Dis.* 2021;8(s2):S205–S222. doi: 10.3233/JND-210713
45. Gallert S-M, Fölsch M, Mavrommatis L, et al. Proteomics of Duchenne muscular dystrophy patient iPSC-derived skeletal muscle cells reveal differential expression of cytoskeletal and extracellular matrix proteins. *Cells.* 2025;14(21):1688. doi: 10.3390/cells14211688
- **Thorough proteomic analysis of pluripotent stem cell-derived dystrophic cell cultures.**
46. Shahin-Shamsabadi A, Cappuccitti J. In vivo-like scaffold-free 3D in vitro models of muscular dystrophies: the case for anchored cell sheet engineering in personalized medicine. *Adv Healthc Mater.* 2025;14(12):e2404465. doi: 10.1002/adhm.202404465
47. Nadarajah VD, van Putten M, Chaouch A, et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). *Neuromuscul Disord.* 2011;21(8):569–578. doi: 10.1016/j.nmd.2011.05.011

- **Proteomic identification of MMP-9 as a fibrosis marker in DMD.**
- 48. Cynthia Martin F, Hiller M, Spitali P, et al. Fibronectin is a serum biomarker for Duchenne muscular dystrophy. *Proteomics Clin Appl.* 2014;8(3–4):269–278. doi: [10.1002/prca.201300072](https://doi.org/10.1002/prca.201300072)
- **Proteomic identification of fibronectin as a DMD serum marker of reactive myofibrosis.**
- 49. Rouillon J, Zocevic A, Leger T, et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. *Neuromuscul Disord.* 2014;24(7):563–573. doi: [10.1016/j.nmd.2014.03.012](https://doi.org/10.1016/j.nmd.2014.03.012)
- **Proteomic identification of titin fragments as a DMD urine marker.**
- 50. Hathout Y, Brody E, Clemens PR, et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. *Proc Natl Acad Sci USA.* 2015;112(23):7153–7158. doi: [10.1073/pnas.1507719112](https://doi.org/10.1073/pnas.1507719112)
- 51. Rouillon J, Poupilot J, Zocevic A, et al. Serum proteomic profiling reveals fragments of MYO3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. *Hum Mol Genet.* 2015;24(17):4916–4932. doi: [10.1093/hmg/ddv214](https://doi.org/10.1093/hmg/ddv214)
- **Proteomic identification of MYO3 as a promising DMD serum marker.**
- 52. Oonk S, Spitali P, Hiller M, et al. Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients. *Proteomics Clin Appl.* 2016;10(3):290–299. doi: [10.1002/prca.201500044](https://doi.org/10.1002/prca.201500044)
- 53. Burch PM, Pogoryelova O, Palandra J, et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. *J Neurol.* 2017;264(3):541–553. doi: [10.1007/s00415-016-8379-6](https://doi.org/10.1007/s00415-016-8379-6)
- 54. Alayi TD, Tawalbeh SM, Ogundele M, et al. Tandem mass Tag-based serum proteome profiling for biomarker discovery in young Duchenne muscular dystrophy boys. *ACS Omega.* 2020;5(41):26504–26517. doi: [10.1021/acsomega.0c03206](https://doi.org/10.1021/acsomega.0c03206)
- 55. Nimer RM, Sumaily KM, Almuslat A, et al. Dystrophin protein quantification as a Duchenne muscular dystrophy diagnostic biomarker in dried blood spots using multiple reaction monitoring tandem mass spectrometry: a preliminary study. *Molecules.* 2022;27(12):3662. doi: [10.3390/molecules27123662](https://doi.org/10.3390/molecules27123662)
- 56. Rossi R, Johansson C, Heywood W, et al. A proof of principle proteomic study detects dystrophin in human plasma: implications in DMD diagnosis and clinical monitoring. *Int J Mol Sci.* 2023;24(6):5215. doi: [10.3390/ijms24065215](https://doi.org/10.3390/ijms24065215)
- 57. Johansson C, Hunt H, Signorelli M, et al. Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers. *Clin Proteomics.* 2023;20(1):23. doi: [10.1186/s12014-023-09412-1](https://doi.org/10.1186/s12014-023-09412-1)
- 58. Johansson C, Schrama EJ, Kotel D, et al. Contrasting Becker and Duchenne muscular dystrophy serum biomarker candidates by using data independent acquisition LC-MS/MS. *Skelet Muscle.* 2025;15(1):15. doi: [10.1186/s13395-025-00385-3](https://doi.org/10.1186/s13395-025-00385-3)
- 59. Dowling P, Negroni E, Trollet C, et al. Serum protein biomarker signature of Duchenne muscular dystrophy. *Eur J Transl Myol.* 2025;35(2):13956. doi: [10.4081/ejtm.2025.13956](https://doi.org/10.4081/ejtm.2025.13956)
- 60. Ayoglu B, Chaouch A, Lochmüller H, et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. *EMBO Mol Med.* 2014;6(7):918–936. doi: [10.15252/emmm.201303724](https://doi.org/10.15252/emmm.201303724)
- 61. Spitali P, Hettne K, Tsonaka R, et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. *J Cachexia Sarcopenia Muscle.* 2018;9(4):715–726. doi: [10.1002/jcsm.12304](https://doi.org/10.1002/jcsm.12304)
- **Comprehensive proteomic analysis of DMD serum.**
- 62. Parolo S, Marchetti L, Lauria M, et al. Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in Duchenne muscular dystrophy. *PLOS ONE.* 2018;13(3):e0194225. doi: [10.1371/journal.pone.0194225](https://doi.org/10.1371/journal.pone.0194225)
- 63. Ikelaar NA, Barnard AM, Eng SWM, et al. Large-scale serum protein biomarkers discovery associated with function and clinical milestones in Duchenne muscular dystrophy. *Nat Commun.* 2025;16(1):9073. doi: [10.1038/s41467-025-64146-y](https://doi.org/10.1038/s41467-025-64146-y)
- 64. Hathout Y, Conklin LS, Seol H, et al. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. *Sci Rep.* 2016;6:31727. doi: [10.1038/srep31727](https://doi.org/10.1038/srep31727)
- 65. Hathout Y, Liang C, Ogundele M, et al. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy. *Sci Rep.* 2019;9(1):12167. doi: [10.1038/s41598-019-48548-9](https://doi.org/10.1038/s41598-019-48548-9)
- 66. Willis AB, Zelikovich AS, Sufit R, et al. Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy. *Sci Rep.* 2024;14(1):28745. doi: [10.1038/s41598-024-79024-8](https://doi.org/10.1038/s41598-024-79024-8)
- **Identification of biomarkers of steroid treatment in DMD.**
- 67. Ahmadiharchegani F, Tobin RA, Degan C, et al. Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naïve Duchenne muscular dystrophy patients. *Sci Rep.* 2025;15(1):39997. doi: [10.1038/s41598-025-23758-6](https://doi.org/10.1038/s41598-025-23758-6)
- 68. Murphy S, Dowling P, Zweyer M, et al. Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. *Int J Mol Med.* 2017;39(6):1357–1370. doi: [10.3892/ijmm.2017.2952](https://doi.org/10.3892/ijmm.2017.2952)
- 69. Dowling P, Gargan S, Zweyer M, et al. Proteomic profiling of fatty acid binding proteins in muscular dystrophy. *Expert Rev Proteomics.* 2020;17(2):137–148. doi: [10.1080/14789450.2020.1732214](https://doi.org/10.1080/14789450.2020.1732214)
- 70. Dowling P, Gargan S, Zweyer M, et al. Proteomic profiling of carbonic anhydrase CA3 in skeletal muscle. *Expert Rev Proteomics.* 2021;18(12):1073–1086. doi: [10.1080/14789450.2021.2017776](https://doi.org/10.1080/14789450.2021.2017776)
- 71. Dowling P, Bouragba D, Negroni E, et al. Proteomic profiling of myofiber repair annexins and their role in Duchenne muscular dystrophy. *Proteomics.* 2025:e70073. doi: [10.1002/pmic.70073](https://doi.org/10.1002/pmic.70073)
- 72. Dowling P, Swandulla D, Ohlndieck K. Mass spectrometry-based proteomic technology and its application to study skeletal muscle cell Biology. *Cells.* 2023;12(21):2560. doi: [10.3390/cells12212560](https://doi.org/10.3390/cells12212560)
- 73. Carr SJ, Zahedi RP, Lochmüller H, et al. Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy. *Proteomics Clin Appl.* 2018;12(2). doi: [10.1002/prca.201700071](https://doi.org/10.1002/prca.201700071)
- 74. Zweyer M, Sabir H, Dowling P, et al. Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers. *Histol Histopathol.* 2022;37(2):101–116. doi: [10.14670/HH-18-403](https://doi.org/10.14670/HH-18-403)
- 75. Gargan S, Dowling P, Zweyer M, et al. Proteomic identification of markers of membrane repair, regeneration and fibrosis in the aged and Dystrophic Diaphragm. *Life (Basel).* 2022;12(11):1679. doi: [10.3390/life12111679](https://doi.org/10.3390/life12111679)
- 76. Dowling P, Gargan S, Zweyer M, et al. Extracellular matrix proteomics: the mdx-4cv mouse diaphragm as a surrogate for studying myofibrosis in dystrophinopathy. *Biomolecules.* 2023;13(7):1108. doi: [10.3390/biom13071108](https://doi.org/10.3390/biom13071108)
- 77. Tamiyakul H, Kemter E, Kösters M, et al. Progressive proteome changes in the myocardium of a pig model for Duchenne muscular dystrophy. *iScience.* 2020;23(9):101516. doi: [10.1016/j.isci.2020.101516](https://doi.org/10.1016/j.isci.2020.101516)
- 78. Holland A, Ohlndieck K. Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathy. *Biomed Res Int.* 2014;2014:1–15. doi: [10.1155/2014/246195](https://doi.org/10.1155/2014/246195)
- 79. Murphy S, Dowling P, Zweyer M, et al. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy. *J Proteomics.* 2016;145:24–36. doi: [10.1016/j.jprot.2016.03.011](https://doi.org/10.1016/j.jprot.2016.03.011)
- 80. Burch PM, Pogoryelova O, Goldstein R, et al. Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. *J Neuromuscul Dis.* 2015;2(3):241–255. doi: [10.3233/JND-140066](https://doi.org/10.3233/JND-140066)

81. Goldstein RA. Skeletal muscle injury biomarkers: assay qualification efforts and translation to the clinic. *Toxicol Pathol.* 2017;45(7):943–951. doi: [10.1177/0192623317738927](https://doi.org/10.1177/0192623317738927)
82. Burlo F, Grigoletto V, Pastore S, et al. Elevated creatine kinase is mainly harmless in children but persistent and severe hyperCKaemia should raise suspicions of serious muscle damage. *Acta Paediatr.* 2023;112(7):1592–1593. doi: [10.1111/apa.16755](https://doi.org/10.1111/apa.16755)
83. Awano H, Nambu Y, Itoh C, et al. Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy. *Muscle Nerve.* 2024;69(5):604–612. doi: [10.1002/mus.28073](https://doi.org/10.1002/mus.28073)
84. Melisi N, Gage MJ. Urinary titin represents an exciting biomarker for assessment of muscle health. *J Muscle Res Cell Motil.* 2025;46(4):379–387. doi: [10.1007/s10974-025-09710-1](https://doi.org/10.1007/s10974-025-09710-1)
85. Signorelli M, Ayoglu B, Johansson C, et al. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. *J Cachexia Sarcopenia Muscle.* 2020;11(2):505–517. doi: [10.1002/jcsm.12517](https://doi.org/10.1002/jcsm.12517)
- **Characterization of MDH2 as a promising DMD biomarker.**
86. Tidball JG, Welc SS, Wehling-Henricks M. Immunobiology of inherited muscular dystrophies. *Compr Physiol.* 2018;8(4):1313–1356. doi: [10.1002/cphy.c170052](https://doi.org/10.1002/cphy.c170052)
87. Riddell DO, Hildyard JCV, Harron RCM, et al. Serum inflammatory cytokines as disease biomarkers in the DE50-MD dog model of Duchenne muscular dystrophy. *Dis Model Mech.* 2022;15(12):dmm049394. doi: [10.1242/dmm.049394](https://doi.org/10.1242/dmm.049394)
88. de Souza Costa AD, Vermeulen-Serpa KM, Batista Marinho KM, et al. Persistent inflammation and nutritional status in Duchenne muscular dystrophy. *Clin Nutr ESPEN.* 2024;61:393–398. doi: [10.1016/j.clnesp.2024.04.014](https://doi.org/10.1016/j.clnesp.2024.04.014)
89. Amthor H. Other innovative therapies in Duchenne muscular dystrophy. *Arch Pediatr.* 2025;32(7S1):S758–S763. doi: [10.1016/S0929-693X\(25\)00255-6](https://doi.org/10.1016/S0929-693X(25)00255-6)
90. Messina S, Vita GL. Clinical management of Duchenne muscular dystrophy: the state of the art. *Neurol Sci.* 2018;39(11):1837–1845. doi: [10.1007/s10072-018-3555-3](https://doi.org/10.1007/s10072-018-3555-3)
91. Wahbi K. Cardiac care in Duchenne muscular dystrophy. *Arch Pediatr.* 2025;32(7S1):S720–S724. doi: [10.1016/S0929-693X\(25\)00249-0](https://doi.org/10.1016/S0929-693X(25)00249-0)
92. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol.* 2018;17(3):251–267. doi: [10.1016/S1474-4422\(18\)30024-3](https://doi.org/10.1016/S1474-4422(18)30024-3)
93. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol.* 2018;17(4):347–361. doi: [10.1016/S1474-4422\(18\)30025-5](https://doi.org/10.1016/S1474-4422(18)30025-5)
94. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol.* 2018;17(5):445–455. doi: [10.1016/S1474-4422\(18\)30026-7](https://doi.org/10.1016/S1474-4422(18)30026-7)
95. Prigent H. Respiratory care in Duchenne muscular dystrophy. *Arch Pediatr.* 2025;32(7S1):S725–S731. doi: [10.1016/S0929-693X\(25\)00250-7](https://doi.org/10.1016/S0929-693X(25)00250-7)
96. Fontaine-Carbonnel S. Corticosteroid treatment in Duchenne muscular dystrophy. *Arch Pediatr.* 2025;32(7S1):S745–S751. doi: [10.1016/S0929-693X\(25\)00253-2](https://doi.org/10.1016/S0929-693X(25)00253-2)
97. Landon G, Stimpson G, Guglieri M, et al. Observational study of changes to glucocorticosteroid prescribing patterns in Duchenne muscular dystrophy in the UK over the last decade. *J Neurol Neurosurg Psychiatry.* 2025;96(8):794–801. doi: [10.1136/jnnp-2024-335223](https://doi.org/10.1136/jnnp-2024-335223)
98. Ibrahim MS, Abdelwahab OA, Elawfi B, et al. Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. *Neurol Sci.* 2025;46(5):2249–2262. doi: [10.1007/s10072-024-07939-1](https://doi.org/10.1007/s10072-024-07939-1)
99. Aartsma-Rus A. Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy. *Front Cell Dev Biol.* 2025;12:1514898. doi: [10.3389/fcell.2024.1514898](https://doi.org/10.3389/fcell.2024.1514898)
100. Bertoldi M, Albamonte E, Bello L, et al. Histone deacetylases in Duchenne muscular dystrophy: a role in the mechanism of disease and a target for inhibition. *Clin Epigenet.* 2025;18(1):9. doi: [10.1186/s13148-025-02031-7](https://doi.org/10.1186/s13148-025-02031-7)
101. Dostal C, Reiner J, Antunes Goncalves AI, et al. Targeting skeletal muscle in Duchenne muscular dystrophy: integrating in silico and experimental approaches to sodium-glucose cotransporter-2 inhibition. *Am J Pathol.* 2025;196(3):S745–765. doi: [10.1016/j.ajpath.2025.11.002](https://doi.org/10.1016/j.ajpath.2025.11.002)
102. Wu R, Song Y, Wu S, et al. Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. *Fundam Res.* 2022;2(6):885–893. doi: [10.1016/j.fmre.2022.07.004](https://doi.org/10.1016/j.fmre.2022.07.004)
103. Mondello S, McGill A, Lu A, et al. Exploring the evidence for the use of protein biomarkers of muscular damage and disease progression in Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis protocol. *BMJ Open.* 2025;15(11):e105983. doi: [10.1136/bmjopen-2025-105983](https://doi.org/10.1136/bmjopen-2025-105983)
104. Duan D, Herzog RW. Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: underlying mechanisms and mitigating strategies. *Mol Ther.* 2026;34(in press):S1893–1908. doi: [10.1016/j.ymthe.2025.12.067](https://doi.org/10.1016/j.ymthe.2025.12.067)